{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:39:34Z","timestamp":1787881174192,"version":"build-2784847793"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002957","name":"Technische Universit\u00e4t Dresden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Dermatology Life Quality Index (DLQI) should be used to assess treatment success in psoriasis (PSO). However, the DLQI does not assess the importance and achievement of treatment goals. The Patient Benefit Index (PBI) is a questionnaire that takes both into account. Currently, there is insufficient knowledge about the modulating variables of the PBI and whether it can complement the assessment of the DLQI. In a longitudinal cohort study, 82 patients with PSO were assessed before and up to sixteen weeks after a new treatment episode. The PBI was compared with patients with atopic dermatitis (AD) (<jats:italic>n<\/jats:italic>\u2009=\u200961). The effects of gender, age, type of therapy, improvement in body surface area (BSA), anxiety\/depression, DLQI and individual coping were assessed. \u201cGetting better skin quickly\u201d was most important in PSO. Improved BSA, anxiety\/depression, DLQI, male gender and initiation of biological therapy had the most positive effects. Partial mediation was found for the reduction of anxiety\/depression and improved coping. The PBI may be considered an appropriate outcome measure of treatment success in PSO, complementing the DLQI. Patients with clinically relevant anxiety\/depression and inadequate coping should be offered adjuvant psychosomatic treatment.<\/jats:p>","DOI":"10.1038\/s41598-024-84794-2","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T01:14:02Z","timestamp":1736471642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Determinants of perceived patient benefit in a longitudinal cohort study of patients with psoriasis and atopic dermatitis"],"prefix":"10.1038","volume":"15","author":[{"given":"Gloria-Beatrice","family":"Wintermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M. J.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Beissert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Weidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"84794_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi, R. et al. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J. Invest. Dermatol. 133, 377\u2013385. https:\/\/doi.org\/10.1038\/jid.2012.339 (2013).","journal-title":"J. Invest. Dermatol."},{"key":"84794_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.genhosppsych.2022.01.006","volume":"75","author":"TL Hedemann","year":"2022","unstructured":"Hedemann, T. L., Liu, X., Kang, C. N. & Husain, M. I. Associations between psoriasis and mental illness: An update for clinicians. Gen. Hosp. Psychiatry 75, 30\u201337. https:\/\/doi.org\/10.1016\/j.genhosppsych.2022.01.006 (2022).","journal-title":"Gen. Hosp. Psychiatry"},{"key":"84794_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1477-7525-4-35","volume":"4","author":"MJ Bhosle","year":"2006","unstructured":"Bhosle, M. J., Kulkarni, A., Feldman, S. R. & Balkrishnan, R. Quality of life in patients with psoriasis. Health Qual. Life Outcomes 4, 35 (2006).","journal-title":"Health Qual. Life Outcomes"},{"key":"84794_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.4103\/ijd.ijd_572_22","volume":"67","author":"K Agarwal","year":"2022","unstructured":"Agarwal, K., Das, A., Das, S. & De, A. Impact of psoriasis on quality of life. Indian J. Dermatol. 67, 387\u2013391. https:\/\/doi.org\/10.4103\/ijd.ijd_572_22 (2022).","journal-title":"Indian J. Dermatol."},{"key":"84794_CR5","unstructured":"Organization, W. H. Global Report on Psoriasis (World Health Organization, 2016)."},{"key":"84794_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/jdv.15920","volume":"34","author":"A Egeberg","year":"2020","unstructured":"Egeberg, A. et al. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis. J. Eur. Acad. Dermatol. Venereol. 34, 39\u201346. https:\/\/doi.org\/10.1111\/jdv.15920 (2020).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"84794_CR7","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1684\/ejd.2013.1988","volume":"23","author":"MA Radtke","year":"2013","unstructured":"Radtke, M. A., Schafer, I., Blome, C. & Augustin, M. Patient benefit index (PBI) in the treatment of psoriasis\u2013results of the National Care Study PsoHealth. Eur. J. Dermatol. 23, 212\u2013217. https:\/\/doi.org\/10.1684\/ejd.2013.1988 (2013).","journal-title":"Eur. J. Dermatol."},{"key":"84794_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","volume":"303","author":"U Mrowietz","year":"2011","unstructured":"Mrowietz, U. et al. Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch. Dermatol. Res. 303, 1\u201310. https:\/\/doi.org\/10.1007\/s00403-010-1080-1 (2011).","journal-title":"Arch. Dermatol. Res."},{"key":"84794_CR9","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/ddg.14507_g","volume":"19","author":"A Nast","year":"2021","unstructured":"Nast, A. et al. Deutsche S3-Leitlinie Zur Therapie Der Psoriasis Vulgaris, adaptiert Von EuroGuiDerm - Teil 2: Therapiemonitoring, besondere klinische situationen und Komorbiditat. J. Dtsch. Dermatol. Ges. 19, 1092\u20131117. https:\/\/doi.org\/10.1111\/ddg.14507_g (2021).","journal-title":"J. Dtsch. Dermatol. Ges"},{"key":"84794_CR10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/jdv.14676","volume":"32","author":"F Rencz","year":"2018","unstructured":"Rencz, F. et al. A detailed analysis of \u2018not relevant\u2019 responses on the DLQI in psoriasis: Potential biases in treatment decisions. J. Eur. Acad. Dermatol. Venereol. 32, 783\u2013790. https:\/\/doi.org\/10.1111\/jdv.14676 (2018).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"84794_CR11","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1111\/bjd.18435","volume":"182","author":"F Rencz","year":"2020","unstructured":"Rencz, F. et al. DLQI-R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea. Br. J. Dermatol. 182, 1167\u20131175. https:\/\/doi.org\/10.1111\/bjd.18435 (2020).","journal-title":"Br. J. Dermatol."},{"key":"84794_CR12","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jamadermatol.2018.5655","volume":"155","author":"JS Barbieri","year":"2019","unstructured":"Barbieri, J. S. & Gelfand, J. M. Influence of not relevant responses on the Dermatology Life Quality Index (DLQI) for patients with psoriasis in the United States. JAMA Dermatol. 155, 743\u2013745. https:\/\/doi.org\/10.1001\/jamadermatol.2018.5655 (2019).","journal-title":"JAMA Dermatol."},{"key":"84794_CR13","doi-asserted-by":"publisher","first-page":"e0235091","DOI":"10.1371\/journal.pone.0235091","volume":"15","author":"N da Silva","year":"2020","unstructured":"da Silva, N. et al. Sex-related impairment and patient needs\/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care. PLoS One. 15, e0235091. https:\/\/doi.org\/10.1371\/journal.pone.0235091 (2020).","journal-title":"PLoS One"},{"key":"84794_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000102029","volume":"215","author":"JM Schmitt","year":"2007","unstructured":"Schmitt, J. M. & Ford, D. E. Role of depression in quality of life for patients with psoriasis. Dermatology 215, 17\u201327. https:\/\/doi.org\/10.1159\/000102029 (2007).","journal-title":"Dermatology"},{"key":"84794_CR15","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaad.2004.04.014","volume":"51","author":"JM Gelfand","year":"2004","unstructured":"Gelfand, J. M. et al. Determinants of quality of life in patients with psoriasis: A study from the US population. J. Am. Acad. Dermatol. 51, 704\u2013708. https:\/\/doi.org\/10.1016\/j.jaad.2004.04.014 (2004).","journal-title":"J. Am. Acad. Dermatol."},{"key":"84794_CR16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1365-2133.2005.06909.x","volume":"154","author":"F Sampogna","year":"2006","unstructured":"Sampogna, F. et al. Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br. J. Dermatol. 154, 325\u2013331. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06909.x (2006).","journal-title":"Br. J. Dermatol."},{"key":"84794_CR17","doi-asserted-by":"publisher","unstructured":"Park, S. Y. & Kim, K. H. What factors influence on Dermatology-Related Life Quality of Psoriasis patients in South Korea? Int. J. Environ. Res. Public. Health 18. https:\/\/doi.org\/10.3390\/ijerph18073624 (2021).","DOI":"10.3390\/ijerph18073624"},{"key":"84794_CR18","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1007\/s12325-022-02124-2","volume":"39","author":"A Armstrong","year":"2022","unstructured":"Armstrong, A. et al. Treatment goals for psoriasis as measured by Patient Benefit Index: Results of a National Psoriasis Foundation Survey. Adv. Ther. 39, 2657\u20132667. https:\/\/doi.org\/10.1007\/s12325-022-02124-2 (2022).","journal-title":"Adv. Ther."},{"key":"84794_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/jdv.16431","volume":"35","author":"M Augustin","year":"2021","unstructured":"Augustin, M. et al. Characteristics and outcomes of patients treated with apremilast in the real world: Results from the APPRECIATE study. J. Eur. Acad. Dermatol. Venereol. 35, 123\u2013134. https:\/\/doi.org\/10.1111\/jdv.16431 (2021).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"84794_CR20","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00403-009-0928-8","volume":"301","author":"M Augustin","year":"2009","unstructured":"Augustin, M. et al. The patient benefit index: A novel approach in patient-defined outcomes measurement for skin diseases. Arch. Dermatol. Res. 301, 561\u2013571. https:\/\/doi.org\/10.1007\/s00403-009-0928-8 (2009).","journal-title":"Arch. Dermatol. Res."},{"key":"84794_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s13555-021-00628-3","volume":"12","author":"TM Klein","year":"2022","unstructured":"Klein, T. M. et al. Real-world experience of patient-relevant benefits and treatment satisfaction with apremilast in patients with psoriasis: An analysis of the APPRECIATE Study. Dermatol. Ther. (Heidelb). 12, 81\u201395. https:\/\/doi.org\/10.1007\/s13555-021-00628-3 (2022).","journal-title":"Dermatol. Ther. (Heidelb)"},{"key":"84794_CR22","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2147\/PPA.S378724","volume":"17","author":"M Augustin","year":"2023","unstructured":"Augustin, M., Sommer, R., Blome, C., Kirsten, N. & Langenbruch, A. Development of a specific variant of Patient Benefit Index (PBI) assessing patient needs, goals and benefits in rosacea treatment. Patient Prefer Adher. 17, 1335\u20131345. https:\/\/doi.org\/10.2147\/PPA.S378724 (2023).","journal-title":"Patient Prefer Adherence"},{"key":"84794_CR23","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/jid.2014.530","volume":"135","author":"FJ Dalgard","year":"2015","unstructured":"Dalgard, F. J. et al. The psychological burden of skin diseases: A cross-sectional multicenter study among dermatological out-patients in 13 European countries. J. Invest. Dermatol. 135, 984\u2013991. https:\/\/doi.org\/10.1038\/jid.2014.530 (2015).","journal-title":"J. Invest. Dermatol."},{"key":"84794_CR24","doi-asserted-by":"publisher","unstructured":"Wintermann, G. B. et al. Childhood trauma and psychosocial stress affect treatment outcome in patients with psoriasis starting a new treatment episode. Front. Psychiatry 13. https:\/\/doi.org\/10.3389\/fpsyt.2022.848708 (2022).","DOI":"10.3389\/fpsyt.2022.848708"},{"key":"84794_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay, A. Y. & Khan, G. K. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 19, 210\u2013216 (1994).","journal-title":"Clin. Exp. Dermatol."},{"key":"84794_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0022-3999(96)00216-4","volume":"42","author":"C Herrmann","year":"1997","unstructured":"Herrmann, C. International experiences with the hospital anxiety and depression scale\u2013a review of validation data and clinical results. J. Psychosom. Res. 42, 17\u201341 (1997). https:\/\/doi.org\/S0022399996002164 [pii].","journal-title":"J. Psychosom. Res."},{"key":"84794_CR27","doi-asserted-by":"crossref","unstructured":"Zigmond, A. S. & Snaith, R. P. The hospital anxiety and depression scale. Acta Psychiatry. Scand. 67 (1983).","DOI":"10.1037\/t03589-000"},{"key":"84794_CR28","first-page":"30","volume":"44","author":"U Stangier","year":"1998","unstructured":"Stangier, U., Gieler, U. & Ehlers, A. Entwicklung einesFragebogens Zur Krankheitsbew\u00e4ltigung Bei Hauterkrankungen (Marburger Haut-Fragebogen, MHF). Diagnostica 44, 30\u201340 (1998).","journal-title":"Diagnostica"},{"key":"84794_CR29","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/1523-1747.ep12384205","volume":"102","author":"AB Fleischer Jr","year":"1994","unstructured":"Fleischer, A. B. Jr., Rapp, S. R., Reboussin, D. M., Vanarthos, J. C. & Feldman, S. R. Patient measurement of psoriasis disease severity with a structured instrument. J. Invest. Dermatol. 102, 967\u2013969 (1994).","journal-title":"J. Invest. Dermatol."},{"key":"84794_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/1523-1747.ep12329912","volume":"106","author":"SR Feldman","year":"1996","unstructured":"Feldman, S. R. et al. The self-administered psoriasis area and severity index is valid and reliable. J. Invest. Dermatol. 106, 183\u2013186 (1996). https:\/\/doi.org\/0022202X96830909 [pii].","journal-title":"J. Invest. Dermatol."},{"key":"84794_CR31","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1001\/archderm.139.3.353","volume":"139","author":"F Sampogna","year":"2003","unstructured":"Sampogna, F. et al. Performance of the self-administered psoriasis area and severity index in evaluating clinical and sociodemographic subgroups of patients with psoriasis. Arch. Dermatol. 139, 353\u2013358. https:\/\/doi.org\/10.1001\/archderm.139.3.353 (2003). discussion 357.","journal-title":"Arch. Dermatol."},{"issue":"Suppl 2","key":"84794_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1468-3083.2011.04411.x","volume":"26","author":"U Mrowietz","year":"2012","unstructured":"Mrowietz, U. Implementing treatment goals for successful long-term management of psoriasis. J. Eur. Acad. Dermatol. Venereol. 26(Suppl 2), 12\u201320. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04411.x (2012).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"84794_CR33","doi-asserted-by":"publisher","unstructured":"Feldman, S. R. & Krueger, G. G. Psoriasis assessment tools in clinical trials. Ann. Rheum. Dis. 64(Suppl 2), ii65\u2013ii68. https:\/\/doi.org\/10.1136\/ard.2004.031237 (2005). (discussion ii69\u201373).","DOI":"10.1136\/ard.2004.031237"},{"key":"84794_CR34","doi-asserted-by":"publisher","unstructured":"Severity scoring of atopic dermatitis: The SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 186, 23\u201331. https:\/\/doi.org\/10.1159\/000247298 (1993).","DOI":"10.1159\/000247298"},{"key":"84794_CR35","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/bjd.15641","volume":"177","author":"R Chopra","year":"2017","unstructured":"Chopra, R. et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br. J. Dermatol. 177, 1316\u20131321. https:\/\/doi.org\/10.1111\/bjd.15641 (2017).","journal-title":"Br. J. Dermatol."},{"issue":"Suppl 2","key":"84794_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1610-0379.2011.07680.x","volume":"9","author":"A Nast","year":"2011","unstructured":"Nast, A. et al. S3-guidelines for the treatment of psoriasis vulgaris update 2011. J. Dtsch. Dermatol. Ges. 9(Suppl 2), 1\u2013104. https:\/\/doi.org\/10.1111\/j.1610-0379.2011.07680.x (2011).","journal-title":"J. Dtsch. Dermatol. Ges"},{"key":"84794_CR37","unstructured":"Hayes, A. F. Introduction to Mediation, Moderation, and Conditional Process Analysis: A regression-based Perspective 2nd edn (The Guilford Press, 2018)."},{"key":"84794_CR38","unstructured":"Hayes, A. F. Introduction to Mediation, Moderation, and Conditional Process Analysis: A regression-based Approach (Guilford, 2017)."},{"key":"84794_CR39","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1046\/j.1365-2133.2000.03469.x","volume":"142","author":"M Scharloo","year":"2000","unstructured":"Scharloo, M. et al. Patients\u2019 illness perceptions and coping as predictors of functional status in psoriasis: A 1-year follow-up. Br. J. Dermatol. 142, 899\u2013907. https:\/\/doi.org\/10.1046\/j.1365-2133.2000.03469.x (2000).","journal-title":"Br. J. Dermatol."},{"key":"84794_CR40","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","volume":"41","author":"F Faul","year":"2009","unstructured":"Faul, F., Erdfelder, E., Buchner, A. & Lang, A. G. Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. Behav. Res. Methods. 41, 1149\u20131160. https:\/\/doi.org\/10.3758\/BRM.41.4.1149 (2009).","journal-title":"Behav. Res. Methods"},{"key":"84794_CR41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00403-015-1613-8","volume":"308","author":"C Blome","year":"2016","unstructured":"Blome, C. et al. Patient-relevant treatment goals in psoriasis. Arch. Dermatol. Res. 308, 69\u201378. https:\/\/doi.org\/10.1007\/s00403-015-1613-8 (2016).","journal-title":"Arch. Dermatol. Res."},{"key":"84794_CR42","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/jdv.12154","volume":"28","author":"A Langenbruch","year":"2014","unstructured":"Langenbruch, A. et al. Quality of health care of atopic eczema in Germany: Results of the national health care study AtopicHealth. J. Eur. Acad. Dermatol. Venereol. 28, 719\u2013726. https:\/\/doi.org\/10.1111\/jdv.12154 (2014).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"84794_CR43","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00403-012-1256-y","volume":"304","author":"J Feuerhahn","year":"2012","unstructured":"Feuerhahn, J., Blome, C., Radtke, M. & Augustin, M. Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis. Arch. Dermatol. Res. 304, 433\u2013441. https:\/\/doi.org\/10.1007\/s00403-012-1256-y (2012).","journal-title":"Arch. Dermatol. Res."},{"key":"84794_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19927","author":"S Gerdes","year":"2024","unstructured":"Gerdes, S. et al. Effectiveness, safety and impact of guselkumab on sexuality and perceived stigmatization in patients with psoriasis in routine clinical practice: Week 28 results from the prospective German multicentre G-EPOSS study. J. Eur. Acad. Dermatol. Venereol. https:\/\/doi.org\/10.1111\/jdv.19927 (2024).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"84794_CR45","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jaad.2024.02.039","volume":"91","author":"A Blauvelt","year":"2024","unstructured":"Blauvelt, A. et al. Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2\/3 randomized trials. J. Am. Acad. Dermatol. 91, 72\u201381. https:\/\/doi.org\/10.1016\/j.jaad.2024.02.039 (2024).","journal-title":"J. Am. Acad. Dermatol."},{"key":"84794_CR46","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2017.08.051","volume":"78","author":"B Strober","year":"2018","unstructured":"Strober, B. et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). J. Am. Acad. Dermatol. 78, 70\u201380. https:\/\/doi.org\/10.1016\/j.jaad.2017.08.051 (2018).","journal-title":"J. Am. Acad. Dermatol."},{"key":"84794_CR47","doi-asserted-by":"publisher","first-page":"2152272","DOI":"10.1080\/09546634.2022.2152272","volume":"34","author":"S Yeroushalmi","year":"2023","unstructured":"Yeroushalmi, S., Chung, M., Bartholomew, E., Hakimi, M. & Koo, J. Comparing the odds of reported depression in psoriasis patients on systemic therapy: A cross-sectional analysis of postmarketing data. J. Dermatolog Treat. 34, 2152272. https:\/\/doi.org\/10.1080\/09546634.2022.2152272 (2023).","journal-title":"J. Dermatolog Treat."},{"key":"84794_CR48","doi-asserted-by":"publisher","unstructured":"Timis, T. L., Beni, L., Mocan, T., Florian, I. A. & Orasan, R. I. Biologic therapies decrease disease severity and improve depression and anxiety symptoms in psoriasis patients. Life (Basel) 13. https:\/\/doi.org\/10.3390\/life13051219 (2023).","DOI":"10.3390\/life13051219"},{"key":"84794_CR49","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/1346-8138.16917","volume":"50","author":"Y Andersch-Bjorkman","year":"2023","unstructured":"Andersch-Bjorkman, Y. et al. Effects of brodalumab on psoriasis and depressive symptoms in patients with insufficient response to TNF-alpha inhibitors. J. Dermatol. 50, 1401\u20131414. https:\/\/doi.org\/10.1111\/1346-8138.16917 (2023).","journal-title":"J. Dermatol."},{"key":"84794_CR50","doi-asserted-by":"publisher","unstructured":"Bournia, V. K. et al. Introduction and switching of biologic agents are associated with antidepressant and anxiolytic medication use: Data on 42 815 real-world patients with inflammatory rheumatic disease. RMD Open 6. https:\/\/doi.org\/10.1136\/rmdopen-2020-001303 (2020).","DOI":"10.1136\/rmdopen-2020-001303"},{"key":"84794_CR51","first-page":"361","volume":"104","author":"J Koo","year":"2019","unstructured":"Koo, J., Ho, R. S. & Thibodeaux, Q. Depression and suicidality in psoriasis and clinical studies of brodalumab: A narrative review. Cutis 104, 361\u2013365 (2019).","journal-title":"Cutis"},{"key":"84794_CR52","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jid.2016.11.032","volume":"137","author":"RT Lewinson","year":"2017","unstructured":"Lewinson, R. T. et al. Depression is Associated with an increased risk of psoriatic arthritis among patients with psoriasis: A population-based study. J. Invest. Dermatol. 137, 828\u2013835. https:\/\/doi.org\/10.1016\/j.jid.2016.11.032 (2017).","journal-title":"J. Invest. Dermatol."},{"key":"84794_CR53","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","volume":"67","author":"Y Dowlati","year":"2010","unstructured":"Dowlati, Y. et al. A meta-analysis of cytokines in major depression. Biol. Psychiatry 67, 446\u2013457. https:\/\/doi.org\/10.1016\/j.biopsych.2009.09.033 (2010).","journal-title":"Biol. Psychiatry"},{"key":"84794_CR54","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bbi.2015.08.005","volume":"51","author":"R Krishnadas","year":"2016","unstructured":"Krishnadas, R. et al. Circulating tumour necrosis factor is highly correlated with brainstem serotonin transporter availability in humans. Brain Behav. Immun. 51, 29\u201338. https:\/\/doi.org\/10.1016\/j.bbi.2015.08.005 (2016).","journal-title":"Brain Behav. Immun."},{"key":"84794_CR55","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/j.1468-3083.2009.03542.x","volume":"24","author":"V Leibovici","year":"2010","unstructured":"Leibovici, V. et al. Well being, psychopathology and coping strategies in psoriasis compared with atopic dermatitis: A controlled study. J. Eur. Acad. Dermatol. Venereol. 24, 897\u2013903 (2010).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"84794_CR56","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1046\/j.1365-2230.2002.01055.x","volume":"27","author":"DG Fortune","year":"2002","unstructured":"Fortune, D. G., Richards, H. L., Main, C. J. & Griffiths, C. E. Patients\u2019 strategies for coping with psoriasis. Clin. Exp. Dermatol. 27, 177\u2013184. https:\/\/doi.org\/10.1046\/j.1365-2230.2002.01055.x (2002).","journal-title":"Clin. Exp. Dermatol."},{"key":"84794_CR57","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1023\/a:1008944108101","volume":"8","author":"A Wahl","year":"1999","unstructured":"Wahl, A., Hanestad, B. R., Wiklund, I. & Moum, T. Coping and quality of life in patients with psoriasis. Qual. Life Res. 8, 427\u2013433. https:\/\/doi.org\/10.1023\/a:1008944108101 (1999).","journal-title":"Qual. Life Res."},{"key":"84794_CR58","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1001\/archderm.139.6.752","volume":"139","author":"DG Fortune","year":"2003","unstructured":"Fortune, D. G. et al. Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch. Dermatol. 139, 752\u2013756. https:\/\/doi.org\/10.1001\/archderm.139.6.752 (2003).","journal-title":"Arch. Dermatol."},{"key":"84794_CR59","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s13555-021-00544-6","volume":"11","author":"C Leonardi","year":"2021","unstructured":"Leonardi, C. et al. Psoriasis severity assessment combining physician and patient reported outcomes: The optimal psoriasis assessment tool. Dermatol. Ther. (Heidelb). 11, 1249\u20131263. https:\/\/doi.org\/10.1007\/s13555-021-00544-6 (2021).","journal-title":"Dermatol. Ther. (Heidelb)"},{"key":"84794_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/PTT.S328575","volume":"12","author":"A Al-Janabi","year":"2022","unstructured":"Al-Janabi, A. & Yiu, Z. Z. N. Biologics in psoriasis: Updated perspectives on long-term safety and risk management. Psoriasis (Auckl) 12, 1\u201314. https:\/\/doi.org\/10.2147\/PTT.S328575 (2022).","journal-title":"Psoriasis (Auckl)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84794-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84794-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84794-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T02:02:21Z","timestamp":1736474541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84794-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["84794"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-84794-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]},"assertion":[{"value":"20 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The present study was conducted in accordance with the Declaration of Helsinki and approved by the local Ethics Committee of the Technische Universit\u00e4t Dresden (EK 524122015).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients gave an informed consent before participating in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All participants gave written consent for their anonymous responses to be publised.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"1553"}}